← Oncology Approval Tracker

FDA DECISION ·

Anktiva + BCG

nogapendekin alfa inbakicept-pmln with Bacillus Calmette–Guérin · Altor BioScience / ImmunityBio

FDA approvalNew or expanded indicationBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This expansion adds high-grade papillary-only tumors to the prior carcinoma-in-situ population.

LAMPGEN ANALYSIS

Why it matters

The expansion reaches patients with high-grade papillary-only disease, whose eligibility previously depended on the presence of carcinoma in situ. FDA discussed how aggressive papillary and in-situ tumors can overlap.

What research teams should watch

Record whether pathology shows papillary-only disease or carcinoma in situ and verify prior BCG exposure and response. Preserve that distinction when reporting outcomes across the expanded population.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

BCG-unresponsive non-muscle-invasive bladder cancer

PRIMARY RECORDS

Sources